{"id":49807,"date":"2022-10-19T16:02:13","date_gmt":"2022-10-19T14:02:13","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/"},"modified":"2022-10-19T16:02:13","modified_gmt":"2022-10-19T14:02:13","slug":"tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/","title":{"rendered":"Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development"},"content":{"rendered":"
\n

SAN FRANCISCO–(BUSINESS WIRE)–Tempo Bioscience, Inc. (\u201cTempo\u201d) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories:\n<\/p>\n

<\/a><\/p>\n\n\n\n
\n

\nTempo-iBMEC\u2122<\/sup>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nHuman iPSC-derived Brain Microvascular Endothelial Cells\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTempo-iPeri\u2122<\/sup>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\n

\nHuman iPSC-derived Pericytes\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nTempo-iBMEC\u2122<\/sup> and Tempo-iPeri\u2122<\/sup> are critical for establishing patient-relevant blood-brain-barrier models to improve the drug development process for a growing number of therapeutic modalities (e.g.,<\/i> small molecules, biologics, gene therapies, CAR-T\/NK therapies, siRNA\/mRNA therapies). Combining these new products with existing products from Tempo, the human blood-brain-barrier is shown to be an orchestrated, dynamic and regulated barrier.\n<\/p>\n

\nThese new products add to the already-existing Tempo Bioscience product lines and expand the TempoStemBank\u2122 <\/sup>Disease Model offerings. Currently, more than twenty-two iPSC-derivative cell types are offered to create patient-relevant disease models. TempoATP\u2122<\/sup>, TempoMito\u2122<\/sup>, TempoCal\u2122<\/sup>, TempoO2<\/sub>\u2122 <\/sup>and TempoVol\u2122<\/sup> biosensors are live-cell reporters of cellular, mitochondrial, and cytotoxicity functions.\n<\/p>\n

\nTempo Bioscience is the sole manufacturer of human iPSC-derived cell types that are engineered using non-viral, nucleic-acids-free, serum-free, and feeder-free technologies. Tempo is committed to advancing technologies that focus on disease modeling and drug safety evaluations using advanced human iPSC-derived cell models in 2D, as well as in 3D as spheroids or organoids. Tempo\u2019s patient-relevant cell models aim to improve drug efficacy evaluations and safety assessments during drug development.\n<\/p>\n

\nAbout Tempo Bioscience, Inc.: Tempo is a technology development focused biotechnology company based in San Francisco, California. Tempo develops and manufactures human iPSC-based biosensor enabling technologies for the biotech, pharmaceutical, and consumer product industries. For more information on Tempo, please visit our home page: https:\/\/www.tempobioscience.com<\/a>. Follow us on LinkedIn.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nTempo Bioscience, Inc.
\n
Angela L. Huang PhD; 650-731-5620\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO–(BUSINESS WIRE)–Tempo Bioscience, Inc. (\u201cTempo\u201d) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories: Tempo-iBMEC\u2122 \u00a0 Human iPSC-derived Brain Microvascular Endothelial Cells Tempo-iPeri\u2122 \u00a0 Human iPSC-derived Pericytes Tempo-iBMEC\u2122 and Tempo-iPeri\u2122 are critical for establishing … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49807","6":"format-standard","7":"category-industry"},"yoast_head":"\nTempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO–(BUSINESS WIRE)–Tempo Bioscience, Inc. (\u201cTempo\u201d) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories: Tempo-iBMEC\u2122 \u00a0 Human iPSC-derived Brain Microvascular Endothelial Cells Tempo-iPeri\u2122 \u00a0 Human iPSC-derived Pericytes Tempo-iBMEC\u2122 and Tempo-iPeri\u2122 are critical for establishing ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-19T14:02:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221019005050\/en\/1605051\/21\/TempoLogo-updated2018TM_copy.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development\",\"datePublished\":\"2022-10-19T14:02:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\\\/\"},\"wordCount\":295,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005050\\\/en\\\/1605051\\\/21\\\/TempoLogo-updated2018TM_copy.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\\\/\",\"name\":\"Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005050\\\/en\\\/1605051\\\/21\\\/TempoLogo-updated2018TM_copy.jpg\",\"datePublished\":\"2022-10-19T14:02:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005050\\\/en\\\/1605051\\\/21\\\/TempoLogo-updated2018TM_copy.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005050\\\/en\\\/1605051\\\/21\\\/TempoLogo-updated2018TM_copy.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/","og_locale":"en_US","og_type":"article","og_title":"Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development - Pharma Trend","og_description":"SAN FRANCISCO–(BUSINESS WIRE)–Tempo Bioscience, Inc. (\u201cTempo\u201d) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories: Tempo-iBMEC\u2122 \u00a0 Human iPSC-derived Brain Microvascular Endothelial Cells Tempo-iPeri\u2122 \u00a0 Human iPSC-derived Pericytes Tempo-iBMEC\u2122 and Tempo-iPeri\u2122 are critical for establishing ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-19T14:02:13+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221019005050\/en\/1605051\/21\/TempoLogo-updated2018TM_copy.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development","datePublished":"2022-10-19T14:02:13+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/"},"wordCount":295,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221019005050\/en\/1605051\/21\/TempoLogo-updated2018TM_copy.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/","url":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/","name":"Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221019005050\/en\/1605051\/21\/TempoLogo-updated2018TM_copy.jpg","datePublished":"2022-10-19T14:02:13+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221019005050\/en\/1605051\/21\/TempoLogo-updated2018TM_copy.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221019005050\/en\/1605051\/21\/TempoLogo-updated2018TM_copy.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/tempo-bioscience-expands-patient-relevant-blood-brain-barrier-models-for-drug-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49807"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49807\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}